Therapeutic Response

ER negative, HER2-negative, and PR negative status confers therapeutic sensitivity to Carboplatin in combination with Cyclophosphamide, Doxorubicin, Paclitaxel, and Pembrolizumab in patients with Invasive Breast Carcinoma.

Statements

Source and description
Keytruda (pembrolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with chemotherapy for the neoadjuvant treatment, and then pembrolizumab continued as a single agent as adjuvant treatment after surgery, of patients with high-risk early-stage triple negative breast cancer (TNBC). This indication is based on KEYNOTE-522 (NCT03036488), a randomized (2:1), multicenter, double-blind, placebo-controlled trial where the chemotherapy regimen consisted of carboplatin, paclitaxel, doxorubicin, and cyclophosphamide.
Pembrolizumab 200mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab 200mg in combination with carboplatin (AUC 5) and weekly paclitaxel 80mg/m^2 followed by doxorubicin and cyclophosphamide (AC 60/600) for reimbursement as a treatment option for the neoadjuvant treatment, and then pembrolizumab as a monotherapy treatment as an adjuvant treatment after surgery, of locally advanced or early stage triple negative breast cancer at high risk of recurrence in adult patients.
Pembrolizumab 200mg, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with weekly carboplatin and paclitaxel followed by doxorubicin and cyclophosphamide for the neoadjuvant treatment, and then continued monotherapy as adjuvant treatment after surgery, of adult patients with locally advanced or early stage triple negative breast cancer at high risk of recurrence.
Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with chemotherapy for reimbursement as a treatment option for the neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, of adult patients with locally advanced or early stage triple negative breast cancer at high risk of recurrence. This cited regimen is specifically for pembrolizumab 400mg, carboplatin AUC 5, and weekly paclitaxel 80mg/m^2 followed by dose dense doxorubicin and cyclophosphamide (AC 60/600) therapy.
Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab in combination with chemotherapy for reimbursement as a treatment option for the neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, of adult patients with locally advanced or early stage triple negative breast cancer at high risk of recurrence. This cited regimen is specifically for pembrolizumab 400mg in combination with weekly carboplatin AUC 1.5 and paclitaxel 80mg/m^2 followed by dose dense doxorubicin and cyclophosphamide (AC 60/600) therapy.